Incidence of chikungunya virus infections among Kenyan children with neurological disease, 2014-2018: A cohort study.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
05 2022
Historique:
received: 25 02 2021
accepted: 19 04 2022
revised: 26 05 2022
pubmed: 14 5 2022
medline: 31 5 2022
entrez: 13 5 2022
Statut: epublish

Résumé

Neurological complications due to chikungunya virus (CHIKV) infection have been described in different parts of the world, with children being disproportionately affected. However, the burden of CHIKV-associated neurological disease in Africa is currently unknown and given the lack of diagnostic facilities in routine care it is possible that CHIKV is an unrecognized etiology among children with encephalitis or other neurological illness. We estimated the incidence of CHIKV infection among children hospitalized with neurological disease in Kilifi County, coastal Kenya. We used reverse transcriptase polymerase chain reaction (RT-PCR) to systematically test for CHIKV in cerebrospinal fluid (CSF) samples from children aged <16 years hospitalized with symptoms of neurological disease at Kilifi County Hospital between January 2014 and December 2018. Clinical records were linked to the Kilifi Health and Demographic Surveillance System and population incidence rates of CHIKV infection estimated. There were 18,341 pediatric admissions for any reason during the 5-year study period, of which 4,332 (24%) had CSF collected. The most common clinical reasons for CSF collection were impaired consciousness, seizures, and coma (47%, 22%, and 21% of all collections, respectively). After acute investigations done for immediate clinical care, CSF samples were available for 3,980 admissions, of which 367 (9.2%) were CHIKV RT-PCR positive. Case fatality among CHIKV-positive children was 1.4% (95% CI 0.4, 3.2). The annual incidence of CHIKV-associated neurological disease varied between 13 to 58 episodes per 100,000 person-years among all children <16 years old. Among children aged <5 years, the incidence of CHIKV-associated neurological disease was 77 per 100,000 person-years, compared with 20 per 100,000 for cerebral malaria and 7 per 100,000 for bacterial meningitis during the study period. Because of incomplete case ascertainment due to children not presenting to hospital, or not having CSF collected, these are likely minimum estimates. Study limitations include reliance on hospital-based surveillance and limited CSF sampling in children in coma or other contraindications to lumbar puncture, both of which lead to under-ascertainment of incidence and of case fatality. In this study, we observed that CHIKV infections are relatively more common than cerebral malaria and bacterial meningitis among children hospitalized with neurological disease in coastal Kenya. Given the wide distribution of CHIKV mosquito vectors, studies to determine the geographic extent of CHIKV-associated neurological disease in Africa are essential.

Sections du résumé

BACKGROUND
Neurological complications due to chikungunya virus (CHIKV) infection have been described in different parts of the world, with children being disproportionately affected. However, the burden of CHIKV-associated neurological disease in Africa is currently unknown and given the lack of diagnostic facilities in routine care it is possible that CHIKV is an unrecognized etiology among children with encephalitis or other neurological illness.
METHODS AND FINDINGS
We estimated the incidence of CHIKV infection among children hospitalized with neurological disease in Kilifi County, coastal Kenya. We used reverse transcriptase polymerase chain reaction (RT-PCR) to systematically test for CHIKV in cerebrospinal fluid (CSF) samples from children aged <16 years hospitalized with symptoms of neurological disease at Kilifi County Hospital between January 2014 and December 2018. Clinical records were linked to the Kilifi Health and Demographic Surveillance System and population incidence rates of CHIKV infection estimated. There were 18,341 pediatric admissions for any reason during the 5-year study period, of which 4,332 (24%) had CSF collected. The most common clinical reasons for CSF collection were impaired consciousness, seizures, and coma (47%, 22%, and 21% of all collections, respectively). After acute investigations done for immediate clinical care, CSF samples were available for 3,980 admissions, of which 367 (9.2%) were CHIKV RT-PCR positive. Case fatality among CHIKV-positive children was 1.4% (95% CI 0.4, 3.2). The annual incidence of CHIKV-associated neurological disease varied between 13 to 58 episodes per 100,000 person-years among all children <16 years old. Among children aged <5 years, the incidence of CHIKV-associated neurological disease was 77 per 100,000 person-years, compared with 20 per 100,000 for cerebral malaria and 7 per 100,000 for bacterial meningitis during the study period. Because of incomplete case ascertainment due to children not presenting to hospital, or not having CSF collected, these are likely minimum estimates. Study limitations include reliance on hospital-based surveillance and limited CSF sampling in children in coma or other contraindications to lumbar puncture, both of which lead to under-ascertainment of incidence and of case fatality.
CONCLUSIONS
In this study, we observed that CHIKV infections are relatively more common than cerebral malaria and bacterial meningitis among children hospitalized with neurological disease in coastal Kenya. Given the wide distribution of CHIKV mosquito vectors, studies to determine the geographic extent of CHIKV-associated neurological disease in Africa are essential.

Identifiants

pubmed: 35550620
doi: 10.1371/journal.pmed.1003994
pii: PMEDICINE-D-21-00976
pmc: PMC9135332
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1003994

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 203077_Z_16_Z
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Annu Rev Entomol. 2020 Jan 7;65:313-332
pubmed: 31594410
Int J Epidemiol. 2012 Jun;41(3):650-7
pubmed: 22544844
BMC Infect Dis. 2021 Feb 18;21(1):186
pubmed: 33602147
Am J Trop Med Hyg. 2018 Jun;98(6):1819-1825
pubmed: 29692295
J Trop Pediatr. 2019 Apr 1;65(2):169-175
pubmed: 29893939
Wellcome Open Res. 2019 Nov 15;4:179
pubmed: 32175480
Genome Med. 2016 Sep 29;8(1):97
pubmed: 27683027
Pediatr Infect Dis J. 2007 Sep;26(9):811-5
pubmed: 17721376
J Gen Virol. 2008 Nov;89(Pt 11):2754-2760
pubmed: 18931072
J Hyg (Lond). 1956 Jun;54(2):177-91
pubmed: 13346078
Clin Microbiol Rev. 2017 Dec 13;31(1):
pubmed: 29237708
Int J Infect Dis. 2017 May;58:69-76
pubmed: 28288924
Open Forum Infect Dis. 2017 May 29;4(3):ofx110
pubmed: 28702473
PLoS Negl Trop Dis. 2014 Jul 17;8(7):e2996
pubmed: 25033077
J Child Neurol. 2008 Sep;23(9):1028-35
pubmed: 18287573
Neurocrit Care. 2017 Dec;27(3):447-457
pubmed: 28741102
Lancet Glob Health. 2013 Sep;1(3):e153-60
pubmed: 24748325
Emerg Infect Dis. 2007 May;13(5):764-7
pubmed: 17553261
PLoS Med. 2008 Mar 18;5(3):e60
pubmed: 18351797
Am J Trop Med Hyg. 2019 May;100(5):1249-1257
pubmed: 30860010
Am J Trop Med Hyg. 2008 Jan;78(1):77-82
pubmed: 18187788
PLoS Negl Trop Dis. 2014 Nov 20;8(11):e3335
pubmed: 25412076
PLoS Negl Trop Dis. 2018 Jun 13;12(6):e0006510
pubmed: 29897898
Clin Infect Dis. 2015 Nov 1;61 Suppl 4:S290-301
pubmed: 26449944
Antiviral Res. 2019 Jun;166:66-81
pubmed: 30905821
BMC Med. 2019 Jul 8;17(1):124
pubmed: 31280724
Lancet. 2001 Jun 2;357(9270):1753-7
pubmed: 11403812
Rev Med Virol. 2018 May;28(3):e1978
pubmed: 29671914
N Engl J Med. 2015 Mar 26;372(13):1231-9
pubmed: 25806915
Sci Rep. 2020 Oct 23;10(1):18196
pubmed: 33097792
Am J Trop Med Hyg. 2007 Jun;76(6):1189-93
pubmed: 17556634
J Child Neurol. 2017 Jul;32(8):712-716
pubmed: 28459170
Lancet. 2019 May 25;393(10186):2146-2154
pubmed: 31000194
Neurology. 2016 Jan 5;86(1):94-102
pubmed: 26609145
PLoS Med. 2007 Aug;4(8):e251
pubmed: 17713980
Am J Trop Med Hyg. 2012 Jan;86(1):171-7
pubmed: 22232469

Auteurs

Doris K Nyamwaya (DK)

KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.

Mark Otiende (M)

KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.

Lilian Mwango (L)

KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.

Symon M Kariuki (SM)

KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.

Berrick Otieno (B)

KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.

Donwilliams O Omuoyo (DO)

KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.

George Githinji (G)

KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.

Barnes S Kitsao (BS)

KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.

Henry K Karanja (HK)

KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.

John N Gitonga (JN)

KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.

Zaydah R de Laurent (ZR)

KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.

Alun Davies (A)

KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.

Salim Mwarumba (S)

KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.

Charles N Agoti (CN)

KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.

Samuel M Thumbi (SM)

Paul G Allen School for Global Animal Health, Washington State University, Washington, United States of America.
Institute of Immunology and Infection Research, University of Edinburgh, Edinburgh, United Kingdom.
Center for Epidemiological Modelling and Analysis, Institute of Tropical and Infectious Diseases, University of Nairobi, Nairobi, Kenya.

Mainga M Hamaluba (MM)

KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.

Charles R Newton (CR)

KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.

Philip Bejon (P)

KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.
Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom.

George M Warimwe (GM)

KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.
Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH